The increased levels of FoxP3+/−Helios+GARP+LAP+ Tregs in LICRC patients could be attributed to the advanced metastatic stage of these patients, and the associated tumour-mediated immunosuppression that could be expected. Here, FOXP3 is linked to neoplasm.